Ferring launches degarelix for prostate cancer in the US
This article was originally published in Scrip
Executive Summary
Ferring Pharmaceuticals has launched its novel prostate cancer drug, degarelix, in the US for the treatment of patients with hormone-sensitive advanced prostate cancer.